[1]汤少梁,焦慧霖.集采政策下慢性病患者感知药品负担及其影响因素研究[J].卫生经济研究,2024,41(09):69-73.
　TANG Shaoliang,JIAO Huilin.Study on Perceived Drug Burden of Chronic Disease Patients and Its Influencing Factors under Centralized Volume-based Procurement Policy[J].Journal Press of Health Economics Research,2024,41(09):69-73.
点击复制

集采政策下慢性病患者感知药品负担及其影响因素研究
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
41
期数:
2024年09期
页码:
69-73
栏目:
药械管理
出版日期:
2024-08-29

文章信息/Info

Title:
Study on Perceived Drug Burden of Chronic Disease Patients and Its Influencing Factors under Centralized Volume-based Procurement Policy
作者:
汤少梁1; 焦慧霖1
1.南京中医药大学卫生经济管理学院，江苏 南京 210023
Author(s):
TANG Shaoliang;  JIAO Huilin
School of Health Economics and Management, Nanjing University of Chinese Medicine, Nanjing Jiangsu 210023, China
关键词:
集中带量采购; 药品负担; 感知; 慢性病患者
Keywords:
centralized volume-based procurement;  drug burden;  perception;  chronic disease patients
分类号:
R19
文献标志码:
A
摘要:
目的：研究集采政策对慢性病患者药品可负担性感知及其影响，为推动药品集采提供循证依据。方法：基于福利经济学理论，分析慢性病患者感知药品负担；通过有序Logit回归，探究患者感知药品负担的影响因素。结果：52.49%的受访者认为药品集采政策实施后药品负担有所减轻；药品负担感知受患者性别、年龄、收入、自评健康、慢性病数量、慢性病患病情况、医保类型、体检和住院服务利用等因素影响，存在地域和人群异质性。结论：药品集采政策能有效减轻慢性病患者药品负担，但政策公平性仍有提升空间；有关部门要做好政策解读和宣传工作，缩小地区间集采政策实施的进度差异，切实减轻患者药品负担。
Abstract:
Objective To study the perceived drug affordability and its influence on chronic disease patients under centralized volume-based procurement policy. Methods Based on the theory of welfare economics, the perceived drug burden of patients with chronic diseases were conducted. Through ordered Logit regression, the influencing factors of the perceived drug burden of patients were explored. Results 52.49% of the respondents believed that the drug burden was reduced after the implementation of centralized volume-based procurement policy. The perceived drug burden of patients was influenced by gender, age, income, self-assessed health, number of chronic diseases, chronic disease prevalence, type of health insurance, medical examination and utilization of hospitalization services, and there was heterogeneity in regions and populations. Conclusion The centralized volume-based procurement policy of drugs can effectively reduce the drug burden of patients with chronic diseases, but there is still room for improvement in the fairness of the policy. The relevant departments should do a good job in interpreting and publicizing the policy, narrow the differences in the progress of the implementation of the centralized volume-based procurement policy between regions.

参考文献/References:

[1] 汤少梁，殷婷.健康扶贫政策背景下慢性病患者药品福利受益归属的公平性及其影响因素研究[J].中国药房，2019，30（08）：1009-1013.
[2] World Health Organization(2018).Noncommunicable diseases[EB/OL].https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases.
[3] Katie G,Jani B,Morrison D,et al.Qualitative systematic reviews of treatment burden in stroke,heart failure and diabetes——methodological challenges and solutions[J].BMC Medical Research Methodology,2013,13(01):10.
[4] Shaoliang T,Yun X,Zhengjun L, et al.Does Economic Support Have an Impact on the Health Status of Elderly Patients With Chronic Diseases in China?——Based on CHARLS(2018) Data Research#13[J].Frontiers in Public Health,2021:9658830-658830.
[5] Carl M ,M V M ,S F M .We need minimally disruptive medicine.[J].BMJ (Clinical research ed.),2009,339(7719):b2803.
[6] Eton D T,Ramalho de Oliveira D,Egginton J S,et al.Building a measurement framework of burden of treatment in complex patients with chronic conditions:a qualitative study[J].Patient Related Outcome Measures,2012:39-49.
[7] 于长永.“4+7”药品带量采购的实践效果与制度隐忧[J].西南民族大学学报（人文社科版），2020，41（04）：34-39.
[8] 舒茜，姚峥嵘，王艳翚，等.药品带量采购政策的利益相关者分析[J].卫生经济研究，2019，36（08）：8-9，12.
[9] 胡善联.带量采购的经济学理论基础和影响分析[J].卫生软科学，2019，33（01）：3-5.
[10] 顾灵娜，蒋茜，路云，等.博弈论视角下药品集中带量采购激励约束机制研究[J].医学与社会，2023，36（12）：138-144.
[11] 马志健.药品带量采购的阻力、压力与垄断力问题探讨[J].医学与哲学，2022，43（06）：25-30.
[12] 马旭东，史岩.福利经济学：缘起、发展与解构[J].经济问题，2018（02）：9-16.
[13] 李毅仁，路云，卢钰琼，等.帕累托改进：我国医保战略性购买的践行路径[J].卫生经济研究，2020，37（10）：8-11.
[14] 王成.分析国家药品集中采购和使用试点政策对我国仿制药企业的影响[J].中国医药工业杂志，2019，50（12）：1519-1523.
[15] 张乐君，沈夕坤，田侃.新制度经济学视角下的我国药品集中采购政策分析[J].中国卫生经济，2020，39（04）：12-14.
[16] 徐赟，汤少梁.药品集中采购背景下慢性病患者药品福利获得感及影响因素[J].中国药房，2022，33（19）：2418-2422.
[17] Huan W,Tong Y H,Qian Z. Does China improve social welfare after implementing the national volume-based procurement?[J].Frontiers in Pharmacology,2023,14:1178026.
[18] Yasushi I.Welfare economics of managing an epidemic:an exposition.[J].Japanese Economic Review(Oxford, England),2021,72(04): 41-43.
[19] 李瑶，刘俊霞，李磊.新农保对农村老年人医疗服务利用的影响及异质性研究[J].农业技术经济，2022（08）：112-124.
[20] 单凌寒，吴群红，李叶，等.中国不同医保制度慢性病患者卫生服务需求、利用、医疗费用和家庭经济风险分析[J].中国公共卫生，2021，37（04）：608-614.
[21] 李玉水，康洽福，韩雅清，等.药品带量采购对患者医疗负担的政策效应研究[J].卫生经济研究，2021，38（04）：28-32.
[22] 宁艳阳.“4+7”药品带量采购面对的三个问题[J].中国卫生，2019（09）：32-34.
[23] 孙文俊，赵子寅，成哲玉，等.药品集中采购政策对药品价格和使用影响的系统综述[J].中国卫生政策研究，2023，16（02）：52-58.

相似文献/References:

[1]郑洋洋,丁锦希,李佳明,等.高值耗材实施集中带量采购的主要障碍及对策研究[J].卫生经济研究,2021,38(4):35.
　ZHENG Yang-yang,DING Jin-xi,LI Jia-ming,et al.Research on the Main Obstacles and Countermeasures of Centralized Quantity Purchase of High Value Medical Consumables[J].Journal Press of Health Economics Research,2021,38(09):35.
[2]周菁菁,谈在祥.国家组织冠脉支架集中带量采购的实施情况及建议[J].卫生经济研究,2021,38(11):3.
　ZHOU Jing-jing,TAN Zai-xiang.Implementation and Suggestions of Centralized Volume-based Procurement of Coronary Stent by National Organization[J].Journal Press of Health Economics Research,2021,38(09):3.
[3]赵予涵,林燕铭,谭艳芬.高值医用耗材治理背景下老年性白内障手术费用研究[J].卫生经济研究,2022,39(1):40.
　ZHAO Yu-han,LIN Yan-ming,TAN Yan-fen.Study on the Cost of Senile Cataract Surgery Under the High-value Medical Consumables Governance[J].Journal Press of Health Economics Research,2022,39(09):40.
[4]冷楠楠,邱英鹏,赵羽西,等.冠脉支架集中带量采购对医疗服务供给的潜在影响分析[J].卫生经济研究,2022,39(5):1.
　LEN Nan-nan,QIU Ying-peng,ZHAO Yu-xi,et al.Analysis of the Potential Impact of the Policy of Centralized Procurement of Coronary Stents on the Provision of Medical Services[J].Journal Press of Health Economics Research,2022,39(09):1.
[5]蒋范黎,肖 月,赵羽西,等.集采背景下经皮冠脉支架植入术成本测算及建议[J].卫生经济研究,2022,39(5):4.
　JIANG Fan-li,XIAO Yue,ZHAO Yu-xi,et al.The Cost Calculation and Analysis of Percutaneous Coronary Intervention under the Background of Centralized Procurement of Stents[J].Journal Press of Health Economics Research,2022,39(09):4.
[6]罗婷婷,王秀英,吴伟旋,等.医院不计价及打包收费耗材的管理现状及对策[J].卫生经济研究,2022,39(5):91.
　LUO Ting-ting,WANG Xiu-ying,WU Wei-xuan,et al.Management Status and Improvement Suggestions of Non-priced and Packaged Charging Consumables[J].Journal Press of Health Economics Research,2022,39(09):91.
[7]黄晓青,王煜昊,王丽娜,等.医用耗材集采背景下按病种分值付费优化方案研究 ——以冠状动脉支架为例[J].卫生经济研究,2022,39(10):16.
　HUANG Xiaoqing,WANG Yuhao,WANG Lina,et al.Research on Policy Optimization of Diagnosis-Intervention Packet Based the Volume-Based Procurement of Medical Comsumables ——Taking Coronary Stents as an Example[J].Journal Press of Health Economics Research,2022,39(09):16.
[8]孙李丽,毛 英,张馨怡,等.国家集中带量采购冠脉支架对住院费用的影响研究[J].卫生经济研究,2023,40(5):55.
　SUN Lili,MAO Ying,ZHANG Xinyi,et al.Study on the Effect of National Centralized Volume-based Procurement of Coronary Stents on Hospitalization Costs[J].Journal Press of Health Economics Research,2023,40(09):55.
[9]李 洁,周胜男,孙源源.基于政策工具理论的中成药集中带量采购政策设计研究[J].卫生经济研究,2023,40(6):13.
　LI Jie,ZHOU Shengnan,SUN Yuanyuan.Study on the Policy Design of Centralized Volume-based Procurement of Chinese Patent Medicine Based on the Policy Tools Theory[J].Journal Press of Health Economics Research,2023,40(09):13.
[10]徐露露,张 钿,陈井婵,等.医保战略性购买对医药企业创新的影响研究[J].卫生经济研究,2023,40(12):7.
　XU Lulu,ZHANG Tian,CHEN Jingchan,et al.Study on the Impact of Strategic Purchase of Medical Insurance on Innovation of Pharmaceutical Enterprises[J].Journal Press of Health Economics Research,2023,40(09):7.

更新日期/Last Update: 2024-08-29